Terence Fenton

Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.

Nachman S, Alvero C, Teppler H, Homony B, Rodgers AJ, Graham BL, Fenton T, Frenkel LM, Browning RS, Hazra R, Wiznia AA.

Lancet HIV. 2018 12. 5(12):e715-e722. PMID: 30527329

Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.

Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, McIntyre J, Gnanashanmugam D, Siberry GK, Coletti AS, Taha TE, Klingman KL, Martinson FE, Owor M, Violari A, Moodley D, Theron GB, Bhosale R, Bobat R, Chi BH, Strehlau R, Mlay P, Loftis AJ, Browning R, Fenton T, Purdue L, Basar M, Shapiro DE, Mofenson LM.

N Engl J Med. 2016 11 03. 375(18):1726-1737. PMID: 27806243

Killer Cell Immunoglobulin-Like Receptor Alleles Alter HIV Disease in Children.

Singh KK, Qin M, Brummel SS, Angelidou K, Trout RN, Fenton T, Spector SA.

PLoS One. 2016. 11(3):e0151364. PMID: 26983081

Heterogeneity of T Cell Responses to Pandemic pH1N1 Monovalent Vaccine in HIV-Infected Pregnant Women.

Weinberg A, Muresan P, Richardson K, Fenton T, Dominguez T, Bloom A, Watts DH, Abzug MJ, Nachman SA, Levin MJ.

AIDS Res Hum Retroviruses. 2015 Nov. 31(11):1170-7. PMID: 26322930

Characterization of functional antibody and memory B-cell responses to pH1N1 monovalent vaccine in HIV-infected children and youth.

Curtis DJ, Muresan P, Nachman S, Fenton T, Richardson KM, Dominguez T, Flynn PM, Spector SA, Cunningham CK, Bloom A, Weinberg A.

PLoS One. 2015. 10(3):e0118567. PMID: 25785995

Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age.

Nachman S, Alvero C, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Rizk ML, Spector SA, Frenkel LM, Worrell C, Handelsman E, Wiznia A.

J Pediatric Infect Dis Soc. 2015 Dec. 4(4):e76-83. PMID: 26582887

Associations of host genetic variants on CD4? lymphocyte count and plasma HIV-1 RNA in antiretroviral naïve children.

Qin M, Brummel S, Singh KK, Fenton T, Spector SA.

Pediatr Infect Dis J. 2014 Sep. 33(9):946-52. PMID: 24797997

Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.

Nachman S, Zheng N, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Wenning L, Spector SA, Frenkel LM, Alvero C, Worrell C, Handelsman E, Wiznia A.

Clin Infect Dis. 2014 Feb. 58(3):413-22. PMID: 24145879

Immunogenicity of Licensed Influenza A (H1N1) 2009 Monovalent Vaccines in HIV-Infected Children and Youth.

Pass RF, Nachman S, Flynn PM, Muresan P, Fenton T, Cunningham CK, Borkowsky W, McAuley JB, Spector SA, Petzold E, Levy W, Siberry GK, Handelsman E, Utech LJ, Weinberg A.

J Pediatric Infect Dis Soc. 2013 Dec. 2(4):352-60. PMID: 24363932

Genetic variants in toll-like receptor 2 (TLR2), TLR4, TLR9, and FC? receptor II are associated with antibody response to quadrivalent meningococcal conjugate vaccine in HIV-infected youth.

Spector SA, Qin M, Lujan-Zilbermann J, Singh KK, Warshaw MG, Williams PL, Jean-Philippe P, Fenton T, Siberry GK.

Clin Vaccine Immunol. 2013 Jun. 20(6):900-6. PMID: 23595505